US 12,458,653 B2
Cannabis based therapeutic and method of use
Nicola Michael Spirtos, Las Vegas, NV (US)
Assigned to YUZU LV LLC, Las Vegas, NV (US)
Filed by YUZU LV LLC, Las Vegas, NV (US)
Filed on Jul. 12, 2023, as Appl. No. 18/220,856.
Application 18/220,856 is a continuation of application No. 18/131,052, filed on Apr. 5, 2023, granted, now 12,303,488.
Application 18/131,052 is a continuation of application No. 16/971,781, granted, now 11,684,604, issued on Jun. 27, 2023, previously published as PCT/US2019/019465, filed on Feb. 25, 2019.
Claims priority of provisional application 62/634,547, filed on Feb. 23, 2018.
Prior Publication US 2023/0346739 A1, Nov. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/352 (2006.01); A61K 31/01 (2006.01); A61K 31/015 (2006.01); A61K 31/05 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/44 (2017.01); A61K 47/46 (2006.01); A61P 25/36 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 31/01 (2013.01); A61K 31/015 (2013.01); A61K 31/05 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/44 (2013.01); A61K 47/46 (2013.01); A61P 25/36 (2018.01)] 6 Claims
 
1. A method of treating chronic pain in a subject using opioids in need thereof, the method comprising orally administering to the subject using opioids in need thereof an effective amount of a liquid pharmaceutical composition in unit dose form comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) and a terpene; wherein the liquid pharmaceutical composition comprises 15-20 mg of the THC per dose, and 10-12 mg of the CBD per dose, thereby treating the chronic pain, and wherein the subject's opioid use decreases by at least 50% within 5 weeks of beginning treatment as determined by morphine equivalency of opioids used.